 Immunotherapy, Adoptive
"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in UAMS Profiles by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 3 | 0 | 3 | | 2024 | 14 | 15 | 29 | | 2023 | 2 | 11 | 13 | | 2022 | 1 | 5 | 6 | | 2021 | 3 | 3 | 6 | | 2020 | 2 | 2 | 4 | | 2019 | 6 | 0 | 6 | | 2018 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2016 | 2 | 1 | 3 | | 2015 | 2 | 0 | 2 | | 2012 | 3 | 0 | 3 | | 2011 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2007 | 0 | 1 | 1 | | 2005 | 2 | 0 | 2 | | 2003 | 2 | 0 | 2 | | 2000 | 2 | 0 | 2 | | 1992 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles over the past ten years.
-
Landi D, Navai SA, Brock RM, Fousek K, Nawas Z, Sanber K, Chauvin-Fleurence C, Bhat RR, Xu S, Krishnamurthy P, Choe M, Campbell ME, Morris JS, Gad AZ, Shree A, Echeandia Marrero AS, Saadeldin AM, Matthew PR, Mullikin D, Bielamowicz K, Kurenbekova L, Major AM, Salsman VS, Byrd TT, Hicks JM, Zhang YJ, Yustein J, Carisey AF, Joseph SK, Ahmed N, Hegde M. A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. Cancer Res Commun. 2025 03 01; 5(3):527-548.
-
Ravi G, Richard S, Kumar S, Atrash S, Liedtke M, Kaur G, Derman B, Bergsagel PL, Mailankody S, McCarthy P, Shrestha A, Kelly LM, Ly T, Das S, Thorpe J, Maier A, Varun D, Navarro G, Burgess MR, Hege K, Koegel AK, Costa LJ. Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T? Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma. Leukemia. 2025 Apr; 39(4):816-826.
-
Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri C, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo R, Nadeem O, Mann H, Kalariya N, Hovanky V, De Avila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr M, Htut M, McGuirk J, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jan 02; 145(1):85-97.
-
Fleischer A, Kurth S, Duell J, Topp M, Strunz PP, Mersi J, Rasche L, Sanges C, Hudecek M, Einsele H, Maatouk I. Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies. J Immunother Cancer. 2024 Dec 22; 12(12).
-
Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.
-
Zhou X, Kortuem KM, Rasche L, Einsele H. Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today? Presse Med. 2025 Mar; 54(1):104265.
-
Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, Cavo M, Martinez Chamorro C, Nooka AK, Martin TG, Karlin L, Leleu X, Bahlis NJ, Besemer B, Pei L, Stein S, Wang Lin SX, Trancucci D, Verona RI, Girgis S, Miao X, Uhlar CM, Chastain K, Garfall AL. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024 Dec 05; 144(23):2375-2388.
-
Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, Landa J, McAvoy DP, Lesokhin AM, Korde N, Hassoun H, Tan CR, Hultcrantz M, Shah GL, Landau HJ, Chung DJ, Scordo M, Eren OC, Dogan A, Giralt SA, Park JH, Rivi?re I, Brentjens RJ, Smith EL, Wang X, Usmani SZ, Mailankody S. Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis. J Clin Oncol. 2025 Feb 10; 43(5):498-504.
-
Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 Feb 10; 43(5):558-566.
-
Frenking JH, Zhou X, Wagner V, Hielscher T, Kauer J, Mai EK, Friedrich MJ, Michel CS, Hajiyianni M, Breitkreutz I, Costello P, Nadeem O, Weinhold N, Goldschmidt H, Schmitt A, Luft T, Schmitt M, M?ller-Tidow C, Topp M, Einsele H, Dreger P, Munshi NC, Sperling AS, Rasche L, Sauer S, Raab MS. EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma. J Immunother Cancer. 2024 Oct 07; 12(10).
-
Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024 08 27; 8(16):4320-4329.
-
Bender JD, Damodharan S, Capitini CM, Moskop A, Toner K, Vatsayan A, Talano JA, Baggott C, Schiff D, Katsanis E, Modi AJ, Quigg TC, Raikar SS, Schultz LM, Pommert L. Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. Blood Adv. 2024 08 13; 8(15):4164-4168.
-
Khurana A, Rosenthal AC, Mohty R, Gaddam M, Bansal R, Hathcock MA, Nedved AN, Durani U, Iqbal M, Wang Y, Paludo J, Villasboas JC, Dingli D, Kourelis T, Leung N, Alkhateeb H, Ruff MW, Gallo de Moraes A, Vergidis P, Herrmann J, Kenderian SS, Bennani NN, Johnston PB, Ansell SM, Lin Y. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management. Blood Cancer J. 2024 08 12; 14(1):136.
-
Hamilton MP, Craig E, Gentille Sanchez C, Mina A, Tamaresis J, Kirmani N, Ehlinger Z, Syal S, Good Z, Sworder B, Schroers-Martin J, Lu Y, Muffly L, Negrin RS, Arai S, Lowsky R, Meyer E, Rezvani AR, Shizuru J, Weng WK, Shiraz P, Sidana S, Bharadwaj S, Smith M, Dahiya S, Sahaf B, Kurtz DM, Mackall CL, Tibshirani R, Alizadeh AA, Frank MJ, Miklos DB. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Adv. 2024 06 25; 8(12):3314-3326.
-
Wesson W, Dima D, Suleman N, Saif MSI, Tabak C, Logan E, Davis JA, McGann M, Furqan F, Mohan M, Rashid A, Abdallah AO, Ullah F, Shune L, Mushtaq MU, Raza S, McGuirk J, Hamadani M, Anwer F, Hashmi H, Ahmed N. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma. Transplant Cell Ther. 2024 Sep; 30(9):876-884.
-
Mohan M, Van Oekelen O, Akhtar OS, Cohen A, Parekh S. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e432204.
-
Al Hadidi S, Heslop HE, Brenner MK, Suzuki M. Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 Aug 07; 32(8):2444-2460.
-
Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD, Kumar S, Martin T. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024 Aug; 25(8):e374-e387.
-
Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Z?hringer A, Sali? H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, W?sch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kort?m M, Rasche L, Einsele H, Meyer PT, Brumberg J, V?lkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, K?hler N, Str?bing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R. Targeting TGF?-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer. 2024 Aug; 5(8):1227-1249.
-
Zhou X, Wagner V, Scheller L, Stanojkovska E, Riedhammer C, Xiao X, Steinhardt MJ, Vogt C, Nerreter S, Eisele F, John M, Munawar U, Kadel SK, Mersi J, Ruckdeschel A, Schimanski S, Haertle L, Waldschmidt JM, Han S, Topp M, Duell J, Einsele H, Riedel A, Kort?m KM, Rasche L. Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study. Br J Haematol. 2024 Sep; 205(3):999-1010.
-
Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024 05 01; 109(5):1514-1524.
-
Elemian S, Al Hadidi S. Targeting GPRC5D in multiple myeloma. Expert Rev Anticancer Ther. 2024 May; 24(5):229-238.
-
Hashmi H, Kumar A, Kharfan-Dabaja MA, Munshi PN, Inamoto Y, DeFilipp Z, Dholaria B, Jain T, Perales MA, Carpenter PA, Hamadani M, Dhakal B, Usmani SZ. ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2024 Aug; 30(8):750-759.
-
Al Hadidi S. Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions. Eur J Cancer. 2024 May; 203:114045.
-
Schinke C. The impressive efficacy of anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma. Chin Clin Oncol. 2024 Jun; 13(3):45.
-
Friend R, Atrash S. Fragile Warriors: Navigating the Delicate Dance of Frailty and CAR-T cell Therapy for Relapsed/Refractory Multiple Myeloma. Transplant Cell Ther. 2024 Mar; 30(3):253-254.
-
Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2024 03 01; 109(3):777-786.
-
Duell J, Leipold AM, Appenzeller S, Fuhr V, Rauert-Wunderlich H, Da Via M, Dietrich O, Toussaint C, Imdahl F, Eisele F, Afrin N, Grundheber L, Einsele H, Weinhold N, Rosenwald A, Topp MS, Saliba AE, Rasche L. Sequential antigen loss and branching evolution in?lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy. Blood. 2024 02 22; 143(8):685-696.
-
Aminov S, Giricz O, Melnekoff DT, Sica RA, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN, Parekh S, Verma A. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency. J Clin Invest. 2024 Feb 20; 134(8).
-
Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, Heuck C, Kane C, Verona R, Moreau P, Bahlis N, Chari A. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024 02 02; 14(1):24.
-
Rasche L, Hudecek M, Einsele H. CAR T-cell therapy in multiple myeloma: mission accomplished? Blood. 2024 01 25; 143(4):305-310.
-
Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini O, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri C, Anderson LD, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees P, Khouri J, McGuirk J, Sidana S, Hansen DK, Patel K. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024 01 09; 8(1):251-259.
-
Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2024 01 02; 134(1).
-
Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol. 2024 Mar; 204(3):887-891.
-
Lin M, Estrada-Merly N, Eapen M, Zamora AE, Pezzin LE, Winn AN, Philip J, Schinke C, Drobyski WR, Anderson LD, D'Souza A. Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States. Bone Marrow Transplant. 2023 12; 58(12):1400-1402.
-
Htut M, Dhakal B, Cohen AD, Martin T, Berdeja JG, Usmani SZ, Agha M, Jackson CC, Madduri D, Deraedt W, Zudaire E, Yeh TM, Xu X, Pacaud L, Akram M, Jagannath S. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. Clin Lymphoma Myeloma Leuk. 2023 12; 23(12):882-888.
-
Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 08 09; 13(1):117.
-
Mohan M, Chakraborty R, Bal S, Nellore A, Baljevic M, D'Souza A, Pappas PG, Berdeja JG, Callander N, Costa LJ. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol. 2023 12; 203(5):736-746.
-
Rajeeve S, Usmani SZ. How Old is Too Old for CAR-T Cell Therapies in Multiple Myeloma? Transplant Cell Ther. 2023 06; 29(6):343-344.
-
Li CMY, Tomita Y, Dhakal B, Li R, Li J, Drew P, Price T, Smith E, Maddern GJ, Fenix KA. Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis. J Immunother Cancer. 2023 04; 11(4).
-
Zhou X, Rasche L, Kort?m KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2023 04 01; 108(4):958-968.
-
Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T Therapies in Solid Tumors: Opportunities and Challenges. Curr Oncol Rep. 2023 05; 25(5):479-489.
-
Guzman G, Pellot K, Reed MR, Rodriguez A. CAR T-cells to treat brain tumors. Brain Res Bull. 2023 05; 196:76-98.
-
Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, Ghodke-Puranik Y, Shah GL, Lesokhin A, Giralt S, Thibaud S, Rossi A, Rodriguez C, Sanchez L, Richter J, Richard S, Cho HJ, Chari A, Usmani SZ, Jagannath S, Shah UA, Mailankody S, Parekh S. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood. 2023 02 16; 141(7):756-765.
-
Garc?a-Guerrero E, Rodr?guez-Lobato LG, Sierro-Mart?nez B, Danhof S, Bates S, Frenz S, Haertle L, G?tz R, Sauer M, Rasche L, Kort?m KM, P?rez-Sim?n JA, Einsele H, Hudecek M, Prommersberger SR. All-trans retinoic acid works synergistically with the ?-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. Haematologica. 2023 02 01; 108(2):568-580.
-
Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023 04 10; 41(11):2087-2097.
-
Al Hadidi S, Cliff ERS. CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma. Eur J Cancer. 2023 03; 182:1-2.
-
Cohen AD, Hari P, Htut M, Berdeja JG, Usmani SZ, Madduri D, Olyslager Y, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau JM, Valluri S, Deraedt W, Akram M, Crawford R, Morrison R, Doward L, Morgan K, Seldam ST, Jakubowiak A, Jagannath S. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):68-77.
-
Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, Usmani SZ, Rivi?re I, Brentjens RJ, Smith EL. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med. 2022 09 29; 387(13):1196-1206.
-
Brown CE, Rodriguez A, Palmer J, Ostberg JR, Naranjo A, Wagner JR, Aguilar B, Starr R, Weng L, Synold TW, Tran V, Wang S, Reik A, D'Apuzzo M, Ressler JA, Zhou Y, Mendel M, Gregory PD, Holmes MC, Tang WW, Forman SJ, Jensen MC, Badie B. Off-the-shelf, steroid-resistant, IL13Ra2-specific CAR T cells for treatment of glioblastoma. Neuro Oncol. 2022 08 01; 24(8):1318-1330.
-
Paul B, Rodriguez C, Usmani SZ. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. Drugs. 2022 Apr; 82(6):613-631.
-
Susanibar Adaniya S, Stadtmauer EA, Cohen AD. CAR T cell therapy for multiple myeloma: What have we learned? Leukemia. 2022 06; 36(6):1481-1484.
-
Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021 10 01; 106(10):2667-2672.
-
Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, Tian H, Yeh TM, Banerjee A, Pacaud L, Garrett A, Haltner A, Cameron C, Van Sanden S, Diels J, Valluri S, Samjoo IA. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021 10; 37(10):1779-1788.
-
van de Donk NWCJ, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov. 2021 07; 2(4):302-318.
-
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 07 24; 398(10297):314-324.
-
Mohan M, Hari P, Dhakal B. Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift. JCO Oncol Pract. 2021 07; 17(7):405-413.
-
Aydin AM, Bunch BL, Beatty M, Hajiran A, Dhillon J, Sarnaik AA, Pilon-Thomas S, Poch MA. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Front Immunol. 2021; 12:628063.
-
Zhou X, Rasche L, Kort?m KM, Danhof S, Hudecek M, Einsele H. Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. Front Immunol. 2020; 11:620312.
-
Dhakal B, Hari PN, Usmani SZ, Hamadani M. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. Bone Marrow Transplant. 2021 01; 56(1):9-19.
-
Zhou X, Bai T, Meckel K, Song J, Jin Y, Kort?m KM, Einsele H, Hou X, Rasche L. COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from W?rzburg and Wuhan. Ann Hematol. 2021 Mar; 100(3):843-846.
-
Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, Manno A, Srikanthan D, Gad AZ, Van Ommeren R, Przelicki D, Richman C, Ramaswamy V, Daniels C, Pallota JG, Douglas T, Joynt ACM, Haapasalo J, Nor C, Vladoiu MC, Kuzan-Fischer CM, Garzia L, Mack SC, Varadharajan S, Baker ML, Hendrikse L, Ly M, Kharas K, Balin P, Wu X, Qin L, Huang N, Stucklin AG, Morrissy AS, Cavalli FMG, Luu B, Suarez R, De Antonellis P, Michealraj A, Rastan A, Hegde M, Komosa M, Sirbu O, Kumar SA, Abdullaev Z, Faria CC, Yip S, Hukin J, Tabori U, Hawkins C, Aldape K, Daugaard M, Maris JM, Sorensen PH, Ahmed N, Taylor MD. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 05; 26(5):720-731.
-
Wu C, Zhang L, Brockman QR, Zhan F, Chen L. Chimeric antigen receptor T cell therapies for multiple myeloma. J Hematol Oncol. 2019 11 21; 12(1):120.
-
Lu YC, Jia L, Zheng Z, Tran E, Robbins PF, Rosenberg SA. Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy. Cancer Immunol Res. 2019 Nov; 7(11):1824-1836.
-
Bukhari A, El Chaer F, Koka R, Singh Z, Hutnick E, Ruehle K, Lee ST, Kocoglu MH, Shanholtz C, Badros A, Hardy N, Yared J, Rapoport AP, Dahiya S. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. Am J Hematol. 2019 10; 94(10):E273-E275.
-
Susanibar Adaniya S, Garfall AL. Multitargeted CAR T-cell therapy in multiple myeloma. Lancet Haematol. 2019 10; 6(10):e494-e495.
-
Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. J Immunother. 2019 05; 42(4):126-135.
-
Leko V, McDuffie LA, Zheng Z, Gartner JJ, Prickett TD, Apolo AB, Agarwal PK, Rosenberg SA, Lu YC. Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. J Immunol. 2019 06 15; 202(12):3458-3467.
-
DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ. Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy. 2018 09; 10(12):1077-1091.
-
Rodriguez A, Brown C, Badie B. Chimeric antigen receptor T-cell therapy for glioblastoma. Transl Res. 2017 09; 187:93-102.
-
Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
-
Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Immunother. 2016 06; 39(5):191-201.
-
Haribhai D, Ziegelbauer J, Jia S, Upchurch K, Yan K, Schmitt EG, Salzman NH, Simpson P, Hessner MJ, Chatila TA, Williams CB. Alternatively Activated Macrophages Boost Induced Regulatory T and Th17 Cell Responses during Immunotherapy for Colitis. J Immunol. 2016 Apr 15; 196(8):3305-17.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|